Breast Cancer Trial, Recruiting NCT06328465 Sponsor: European Institute of Oncology Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06328465
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman (before or after menopause) who has been diagnosed with invasive breast cancer at stage II or III, and your cancer is either HER2-positive or triple-negative
  • You have had surgery to remove the breast cancer, or you received treatment before surgery and still had some cancer remaining when surgery was performed (including a specific type called cT4d)
  • Scans done around the time of your surgery (within about 1 month) showed no signs that the cancer has spread to other parts of your body
  • You have no major other health conditions that would affect your participation
  • You are in excellent general health and able to carry out normal daily activities without any limitations (a measure called ECOG performance status 0)
  • You live close enough to the trial site to attend follow-up appointments
  • You are able to understand the study and are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • You have a reason why you absolutely cannot have an MRI scan (for example, certain metal implants)
  • You have a condition that makes having an MRI scan uncertain or potentially unsafe, unless there is a strong medical reason to proceed (confirm with trial site)
  • You are older than 75 years of age
  • You have had, or currently have, another type of cancer — unless it was a common skin cancer or an early-stage cervical cancer that was fully treated
  • You have an uncontrolled serious illness, such as heart failure, unstable chest pain (angina), or a mental health or personal situation that would make it difficult to follow the study requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Monica Iorfida, MD, European Institute of Oncology

Phone: +390257489970

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
European Institute of Oncology
Registry
ClinicalTrials.gov
Start date
22 November 2019
Est. completion
31 December 2028

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

5-year overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov